Volver a Agenda
Session Chair(s)
Andrew Townshend
Senior Vice President, Alliance Development
Syneos Health, United States
Learning Objective : Define a functional service provider (FSP) model and associated considerations in structuring this type of partnership; Recognize how structures must change both within the CRO and the pharmaceutical partner to support this relationship; Assess the challenges and benefits of converting from one type of partnering model to an FSP relationship and how to manage through the process.
Speaker(s)
Panelist
Rose Kidd
ICON, Ireland
Executive Vice Presdient, Global Quality and Compliance
Panelist
Adrian Otte
KPS Life, United States
Executive Strategic Advisor & Board Member
Panelist
Benjamin Thurmond, JD
Biomarin Pharmaceuticals, United States
Corporate Council
¿Tiene una cuenta?